SynoJoynt™ 1% Sodium Hyaluronate

SynoJoynt™ is a high molecular weight, non-crosslinked sodium hyaluronate derived from bacterial fermentation with excellent safety and tolerability.1 It is indicated for the treatment of pain from osteoarthritis of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics.

Explore the new

SynoJoynt™ Resource Kit

Reference:

1. US Food and Drug Administration. Summary of safety and effectiveness (SSED) for SynoJoynt. Accessed January 5, 2022. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170016B.pdf

INDICATIONS

SYNOJOYNT is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen).

CONTRAINDICATIONS

  • Do not use SYNOJOYNT to treat patients who have a known hypersensitivity to hyaluronan preparations.
  • Do not use to treat patients with knee joint infections or to treat patients with infections or skin disease in the area of the injection site.

WARNINGS

  • Do not concomitantly use disinfectants containing quaternary ammonium salts or chlorhexidine for skin preparations because hyaluronan can precipitate in their presence.
  • Do not inject intravascularly because intravascular injections of SYNOJOYNT may cause systemic adverse events.
View More

SynoJoynt™ is a high molecular weight, non-crosslinked sodium hyaluronate derived from bacterial fermentation with excellent safety and tolerability.1 It is indicated for the treatment of pain from osteoarthritis of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics.

Explore the new

SynoJoynt™ Resource Kit

Reference:

1. US Food and Drug Administration. Summary of safety and effectiveness (SSED) for SynoJoynt. Accessed January 5, 2022. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170016B.pdf

INDICATIONS

SYNOJOYNT is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen).

CONTRAINDICATIONS

  • Do not use SYNOJOYNT to treat patients who have a known hypersensitivity to hyaluronan preparations.
  • Do not use to treat patients with knee joint infections or to treat patients with infections or skin disease in the area of the injection site.

WARNINGS

  • Do not concomitantly use disinfectants containing quaternary ammonium salts or chlorhexidine for skin preparations because hyaluronan can precipitate in their presence.
  • Do not inject intravascularly because intravascular injections of SYNOJOYNT may cause systemic adverse events.
View More
View Scientific Evidence

Educational Resources and Products

SynoJoynt™ 1% Sodium Hyaluronate

Brochures | English | 02/14/2022 | LB1-000343-en-US A

SynoJoynt™ 1% Sodium Hyaluronate

Surgical Technique Animations | 01:57 | English | 07/19/2022 | AN1-000343-en-US C
SynoJoynt™ 1% Sodium Hyaluronate: A Patient’s Guide
Patient Education Literature | English | 02/14/2022 | pLB1-000350-en-US A
Reimbursement Guide for SynoJoynt™ 1% Sodium Hyaluronate
Miscellaneous | English | 02/18/2022 | LB1-000101-en-US C
Videos
(2)
arrow_drop_down
Videos
Documents
(9)
arrow_drop_down
Documents
English
(11)
arrow_drop_down
Languages

Surgical Technique Animations (1)

SynoJoynt™ 1% Sodium Hyaluronate
01:57 | English | 07/19/2022 | AN1-000343-en-US C

Brochures (2)

Orthobiologics New Product & Technique Highlights
English | 06/20/2022 | LB1-000376-en-US A
SynoJoynt™ 1% Sodium Hyaluronate
English | 02/14/2022 | LB1-000343-en-US A

Catalogs (1)

Miscellaneous (3)

Patient Education Literature (3)

SynoJoynt™ Hialuronato sódico al 1%
Spanish | 02/18/2022 | pLB1-000350-es-NT A
SynoJoynt™ 1% 透明质酸钠
Chinese | 02/18/2022 | pLB1-000350-zh-CN A
SynoJoynt™ 1% Sodium Hyaluronate: A Patient’s Guide
English | 02/14/2022 | pLB1-000350-en-US A

Presentation Videos (1)

Evidence for Hyaluronic Acid Viscosupplementation for Osteoarthritis of the Knee
Michael Baria, MD
03:47 | English | 12/12/2022 | VID1-003658-en-US A

Scientific Updates (1)

Hyaluronic Acid Scientific Update
English | 02/14/2022 | DOC1-000653-en-US A

Surgeon Newsletters (1)

Scope This Out, Volume 23, Number 1
English | 03/14/2022 | LN1-000401-en-US A

Customer ServiceLatex Information